Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant radiochemotherapy. The rate of pCR under ICIs combined with neoadjuvant radiochemotherapy was reported around 50%, which means more than half of those patients could not obtain pCR in reality. In order to explore a more effective mode of neoadjuvant therapy for ESCC, we designed this study to evaluate the effect of PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy in local advanced ESCC.
diagnosed with esophageal squamous cell cancer;
staged with cT1N+M0/cT2-3N0-3M0;
experienced no cancer-related treatment;
ECOG 0-1;
diagnosed with other types of cancer during last five years;
have a tendency to bleed;
accepted any type of cancer-related therapy.
Parallel
cadonilizumab combined with neoadjuvant radiochemotherapy
Combination productSubjects randomized to experimental arm will be treated with PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.
neoadjuvant radiochemotherapy
Combination productSubjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.
pCR
pathological complete response
Click on the lead sponsor to view all of their trials.
